Comparative Pharmacology
Head-to-head clinical analysis: DUEXIS versus NEOPROFEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DUEXIS versus NEOPROFEN.
DUEXIS vs NEOPROFEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DUEXIS is a combination of ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, and famotidine, a histamine H2-receptor antagonist that decreases gastric acid secretion. Famotidine mitigates the risk of NSAID-induced gastric ulcers.
Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis and thereby decreasing inflammation, pain, and fever.
One tablet (800 mg ibuprofen/26.6 mg famotidine) orally three times daily.
IV: 10 mg/kg over 15 minutes, followed by 5 mg/kg at 24, 48, and 72 hours after the first dose.
None Documented
None Documented
Ibuprofen: 2-4 hours (terminal); requires every 6-8 hour dosing. Famotidine: 2.5-3.5 hours (normal renal function); prolonged to 20 hours or more in severe renal impairment (CrCl < 30 mL/min).
Terminal elimination half-life is approximately 2.5 to 4 hours in adults. In preterm neonates (target population for Neoprofen), half-life is prolonged due to immature renal function: mean 30.5 hours (range 20–50 hours) after first dose, decreasing to ~15 hours after third dose. Clinical relevance: requires careful dosing intervals in neonates to avoid accumulation.
Ibuprofen: ~1% unchanged in urine, 14% as conjugated metabolites, remainder as oxidative metabolites; <1% excreted in feces. Famotidine: 65-70% unchanged in urine, 30-35% metabolized hepatic; <10% fecal.
Ibuprofen is primarily excreted renally as metabolites (approximately 90% of the dose), with less than 1% excreted unchanged. A small fraction (≤10%) is eliminated via bile/feces. For Neoprofen (ibuprofen lysine specifically used for patent ductus arteriosus), renal excretion accounts for >90% of elimination, predominantly as glucuronide conjugates and hydroxylated metabolites.
Category C
Category C
NSAID/H2 Antagonist Combination
NSAID